Compare Agilysys Inc (AGYS) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Agilysys Inc vs Novo Nordisk A/S — how do they compare? Agilysys Inc trades at $107.52 (market cap $3.00B), while Novo Nordisk A/S trades at $47.23 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 69.3× Agilysys Inc's market cap, and Novo Nordisk A/S pays a 3.81% dividend while Agilysys Inc pays none. Which is the better fit depends on your goals.
| AGYS | NVO | |
|---|---|---|
Market Cap | $3.00B | $207.85B |
Sector | Technology | Health |
52-Week High | $141.12 | $63.98 |
52-Week Low | $62.19 | $35.29 |
Enterprise Value | $2.90B | $222.55B |
Dividend Yield | — | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agilysys (AGYS) trades at $106.14, down 0.79% for the day, with a bullish technical signal from moving averages and a consensus analyst price target of $118.33. Recent Q1 2026 earnings beat expectations with EPS of $0.63 versus $0.4971, and the company raised its full-year outlook, driven by strong subscription revenue growth and deployment progress with key clients like Marriott.
The outlook is positive given robust earnings momentum and 100% buy ratings from analysts, though high valuation multiples (P/E of 70.01) and negative net cash flow in 2025 pose risks. Upside potential exists if subscription-led growth continues, but investors should monitor execution against elevated expectations.
Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.
Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Agilysys Inc
Agilysys provides enterprise software and SaaS solutions for the hospitality industry. Its products specialize in point-of-sale, property management, and inventory systems for hotels, resorts, and cruise lines.
Read more on AGYS →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
